<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663282</url>
  </required_header>
  <id_info>
    <org_study_id>INS068-201</org_study_id>
    <nct_id>NCT04663282</nct_id>
  </id_info>
  <brief_title>A Trial of INS068 in Patients With Type 2 Diabetes Not Adequately Controlled With One or Two Oral Antidiabetics</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of INS068 Injection and Insulin Degludec Subcutaneous Injection Once Daily in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With One or Two Oral Antidiabetics (A Randomized, Open-Label, Two-Arm, Treat-to-Target, Parallel Controlled Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the efficacy and safety of IND068 once daily (QD) in&#xD;
      subjects with type 2 diabetes not adequately controlled with one or two oral antidiabetics&#xD;
      compared to insulin degludec QD for 16 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 4, 2021</start_date>
  <completion_date type="Anticipated">May 7, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 7, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>INS068 campared with Insulin degludec, both in Combination with One or Two Oral Antidiabetics</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in HbA1c</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Change from baseline in Glycosylated Haemoglobin after 16 weeks of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects reaching HbA1c targets</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>HbA1c &lt;7% or HbA1c ≤6.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in FPG</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Change from baseline in FPG after 16 weeks of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>9-point SMPG profiles</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Mean plasma glucose, Postprandial and nocturnal increments, Fluctuation of 9-point SMPG. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner,120 minutes after start of dinner, before bedtime, at 4 am and before breakfast.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-breakfast SMPG</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Mean plasma glucose, Within-subject variability of pre-breakfast SMPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Titration target</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Proportion of subjects and time reaching titration targets</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of hypoglycaemic episodes according to 2017 ADA/EASD classfication</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Classification of hypoglycaemia: Level 1(glucose level below 3.9 mmol/L), Level 2(glucose level below 3.0 mmol/L) and Level 3(Severe hypoglycemia, denotes severe cognitive impairment requiring external assistance for recovery).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of injection site reactions</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>The injection site reactions was assessed during the treatment period of 16 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of adverse events</measure>
    <time_frame>Week 0 to Week 16 + 14 days follow-up</time_frame>
    <description>Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities, no or minimal medical treatment. Moderate: marked symptoms, interference with subject's daily activities，and medical treatment for alleviation without grave or permanent injury to the subject. . Severe: considerable interference with subject's daily activities， and intensive treatment and intervention needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug Antibodies: Anti-INS068 Antibodies</measure>
    <time_frame>Week 0 to Week 16+14 days follow-up</time_frame>
    <description>Number of Participants Positive or Negative for Anti-INS068 Antibodies were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Weight</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Change of body weight was evaluated from Week 0 to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Mass Index</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Change of Body Mass Index was evaluated from Week 0 to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Related Quality of Life Questionnaire (SF -36)</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>Change from baseline in scores of Health-Related Quality of Life Questionnaire after 16 weeks of treatment. The questionnaire contains 36 items across 8 domains and 2 summary scores. Score range: 0 (worst score) to 100 (best score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum INS068 concentration</measure>
    <time_frame>Week 0 to Week 16</time_frame>
    <description>To evaluate PK of INS068</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>INS068</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention: Drug: INS068 injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDeg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: insulin Degludec</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INS068 injection</intervention_name>
    <description>INS068 injected subcutaneously once daily. Treat-to-target dose titration during the trial</description>
    <arm_group_label>INS068</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Degludec</intervention_name>
    <description>Insulin Degludec injected subcutaneously once daily. Treat-to-target dose titration during the trial</description>
    <arm_group_label>IDeg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed consent obtained before any trial-related activities. (Trial-related&#xD;
             activities are any procedure that will not have been performed during normal&#xD;
             management of the subject.)&#xD;
&#xD;
          -  Age is 18-75 years&#xD;
&#xD;
          -  Type 2 diabetes for at least 3 months&#xD;
&#xD;
          -  Treatment with one or two oral anti-diabetic drug (OADs): metformin (stable daily dose&#xD;
             of ≥ 1500 mg or maximum tolerated dose(at least 1000mg dose）), with or without insulin&#xD;
             secretagogue (SU or glinides) or DPP-4 inhibitors or SGLT-2 inhibitors or&#xD;
             alpha-glucosidase inhibitors for at least 8 weeks at a stable dose. The dose(s) of OAD&#xD;
             other than metformin should be minimum half of the daily maximal dose according to&#xD;
             local labelling or maximum tolerated dose .&#xD;
&#xD;
          -  Insulin naïve. short-term insulin treatment (consecutive or cumulative treatment of&#xD;
             ≤14 days) and insulin treatment for gestational diabetes are allowed.&#xD;
&#xD;
          -  HbA1c 7.0-10.0 % (53-85 mmol/mol) (both inclusive)&#xD;
&#xD;
          -  BMI 19-40 kg/m2 (both inclusive)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected allergy or intolerance to the active substance or to any of the&#xD;
             excipients of the investigational medical products&#xD;
&#xD;
          -  Severe hypoglycemia during the previous 6 months.&#xD;
&#xD;
          -  Hospitalization for diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome&#xD;
             during the previous 6 months.&#xD;
&#xD;
          -  Cardiovascular disease within the last 12 months, defined as: stroke, decompensated&#xD;
             heart failure (New York Heart Association [NYHA] class III or IV), myocardial&#xD;
             infarction, or hospitalization for unstable angina pectoris or transient ischemic&#xD;
             attack.&#xD;
&#xD;
          -  Diagnosis of malignant neoplasms (except basal cell or squamous cell skin cancer,&#xD;
             polyps and in-situ carcinomas) within the last 5 years or increased risk of cancer or&#xD;
             relapse of cancer.&#xD;
&#xD;
          -  Any antidiabetic medication other than permitted in the inclusion criteria or any&#xD;
             weight-loss drug within 8 weeks.&#xD;
&#xD;
          -  Systemic or intra-articular corticosteroids treatment within the last 3 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hong Chen, M.D, PhD</last_name>
    <phone>+86 13501791711</phone>
    <email>hong.chen@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Zhu, M.D, PhD</last_name>
    <phone>+86 13380043088</phone>
    <email>zhubo@hrglobe.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>National Research Institute - Huntington Park</name>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <zip>90255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stanley Hsin-Wei Hsia, Doctor</last_name>
      <phone>323-588-1968</phone>
      <email>Stanley.Hsia@nritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Research</name>
      <address>
        <city>Lincoln</city>
        <state>California</state>
        <zip>95648</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Wayne, Doctor</last_name>
      <phone>916-487-8230</phone>
      <email>jwaynemd@ctrsites.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Torrance Clinical Research Institute Inc</name>
      <address>
        <city>Lomita</city>
        <state>California</state>
        <zip>90717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Raikhel, Doctor</last_name>
      <phone>310-373-8120</phone>
      <email>mraikhel@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Research Institute - Wilshire</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90057</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Pablo Frias, Doctor</last_name>
      <phone>213-413-2500</phone>
      <email>Juan.Frias@nritrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ALL Medical Research, LLC</name>
      <address>
        <city>Cooper City</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Lewy-Alterbaum, Doctor</last_name>
      <phone>754-263-2000</phone>
      <email>Drlewy@allmedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Generation of Medical Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karelia Ruiz, Doctor</last_name>
      <phone>305-828-9100</phone>
      <email>kareliar@ngmresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014-3616</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Rondon, Doctor</last_name>
      <phone>305-817-2900</phone>
      <email>Jrondon@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Progressive Medical Research</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Billmeier, Doctor</last_name>
      <phone>386-304-7070</phone>
      <email>Drdavidbillmeier@progressivemedicalresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iowa Diabetes and Endocrinology Research Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anuj Bhargava, Doctor</last_name>
      <phone>515-329-6800</phone>
      <email>abhargava@iderc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endocrinology Associates, Inc</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elena Christofides, Doctor</last_name>
      <phone>614-205-3636</phone>
      <email>christofides@endocrinology-associates.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prestige Clinical Research</name>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <zip>45005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Juno Research, LL</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77040</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vega Damaris, Doctor</last_name>
      <phone>713-779-5494</phone>
      <email>damaris_vega@junoresearch.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Medical Center Office</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rocio Harbison, Doctor</last_name>
      <phone>713-779-5494</phone>
      <email>Rocio_Harbison@junoresearch.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juno Research, LLC - Southwest Houston Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey Lacour, MD</last_name>
      <phone>713-779-5494</phone>
      <email>Audrey_lacour@junoresearch.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trials</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hernan Salazar, Doctor</last_name>
      <phone>210-949-0807</phone>
      <email>hsalazar@ergclinical.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Core Research Group Pty Ltd</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4064</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Colman, Prof.</last_name>
      <phone>+61 39342 7344</phone>
      <email>Peter.Colman@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health (Heidelberg Repatriation Hospital)</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3081</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ekinci Elif, Prof.</last_name>
      <phone>+61 3 9496 4026</phone>
      <email>elif.ekinci@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linong Ji, Doctor</last_name>
      <phone>+86-13910978815</phone>
      <email>jiln@bjmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ke Li, Doctor</last_name>
      <phone>13594155980</phone>
      <email>791450945@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing University Three Gorges Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>404100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weijuan Liu, Bachelor</last_name>
      <phone>13996507758</phone>
      <email>Lwj667755@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hainan General Hospital</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <zip>570311</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daoxiong Chen, Doctor</last_name>
      <phone>+86-13807561755</phone>
      <email>chendaoxiogn@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>LiHui Zhang, Doctor</last_name>
      <phone>15803210962</phone>
      <email>zhanglihui10510@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guijun Qin, Doctor</last_name>
      <phone>13598860123</phone>
      <email>hyqingj@zzu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College, Huazhong University of Scince and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuefeng Yu, Doctor</last_name>
      <phone>13986070673</phone>
      <email>xfyu188@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital,The Affiliated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yan Bi, Doctor</last_name>
      <phone>13655176388</phone>
      <email>biyan@nju.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongda Hospital Affiliated to Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yao Wang, Doctor</last_name>
      <phone>13851545593</phone>
      <email>wang_yao100@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jingdong Liu, master</last_name>
      <phone>13970921669</phone>
      <email>easd04ljd@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Of China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ling Li, Doctor</last_name>
      <phone>+86-18940251181</phone>
      <email>liling@sj-hospital.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Xu, Doctor</last_name>
      <phone>+86-18092746638</phone>
      <email>xujingjdey85@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Xuhui District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200031</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhiwen Liu, Master</last_name>
      <phone>+86-13774454549</phone>
      <email>Liuzhiwen1203@aliyun.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Putuo District Central Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200062</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Lei, Doctor</last_name>
      <phone>+86-13611756518</phone>
      <email>leitao5899@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Yang, Doctor</last_name>
      <phone>13603512746</phone>
      <email>yangjlm@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>West China Hospital,Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhang, Doctor</last_name>
      <phone>+86-18980606700</phone>
      <email>492032132@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yibin Second People's Hospital</name>
      <address>
        <city>Yibin</city>
        <state>Sichuan</state>
        <zip>644000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chengxia Jiang, Master</last_name>
      <phone>13684170789</phone>
      <email>jcx0405@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>China</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>October 28, 2021</last_update_submitted>
  <last_update_submitted_qc>October 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

